AstraZeneca · 1 day ago
Analytical Development Intern (Graduate-Level)
AstraZeneca is seeking Master's and Doctoral students for a 12-week internship role at their Alexion: AstraZeneca Rare Disease site in New Haven, CT. The role involves leading and executing comparability and forced degradation studies, as well as developing and optimizing analytical methods for biotherapeutic candidates.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Lead and execute comparability and forced degradation studies, including study design, sample preparation, data analysis, and reporting
Lead and perform enrichment, fractionation, and characterization of protein variants (e.g., charge and size variants) using techniques such as SEC, CE-SDS, IEX, and MS
Develop, optimize, and document analytical/characterization methods for biotherapeutic candidates, including drafting protocols/reports and establishing system suitability/acceptance criteria
Qualification
Required
Master's and Doctoral students studying Biochemistry, Chemistry or Analytical Chemistry, Chemical Engineering, Molecular Biology, Pharmaceutical Science, Bioengineering/Biotechnology, or a related discipline
Candidates must have an expected graduation date after August 2026
Basic laboratory skills such as pipetting and dilution required
US Work Authorization is required at time of application
Ability to report onsite to New Haven, CT site 4-5 days per week. This role will not provide relocation assistance
Preferred
Knowledge and understanding of separation science, including liquid chromatography (Size-Exclusion Chromatography, Ion-Exchange Chromatography)/Capillary Isoelectric Focusing/Imaged Capillary Electrophoresis is preferred
Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Leadership Team
Recent News
2026-01-09
2026-01-09
News Powered by Cision
2026-01-08
Company data provided by crunchbase